CompletedNo phase
Microvascular Function in Patients Undergoing Transcatheter Aortic Valve Implant (TAVI) for Severe Symptomatic Aortic Stenosis: Association With Myocardial Fibrosis
Key facts
- Who runs it
- Matteo Montorfano
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 75 people enrolled
- Started
- 8 Jul 2021
- Ended
- 30 Jul 2025
- Type of study
- Interventional
- Treatments tested
- coronary physiology
- Record updated
- 30 March 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- All patients referred to IRCCS Ospedale San Raffaele who are candidates to receive a TAVI implant for severe, symptomatic aortic stenosis under current appropriateness criteria and clinical practice guidelines will be considered eligible to take part in the study
Who cannot take part
- Concomitant use of dypiridamole
- Pre-existing known disease determining a prognosis quo ad vitam shorter than the follow up of the present study
- Significant chronic kidney disease (estimated glomerular filtration rate <30 ml/min)
- Known allergic reactions
- Unstable angina
- Acutely decompensated heart failure
- Chronic obstructive pulmonary disease with bronchospasm
- Long QT syndrome
- Age <18 years
- Inability to express informed consent to take part in the present study
- Pregnancy or lactation
- Known significant epicardial coronary artery stenosis
- Known contraindication to adenosine administration:
- Second or third degree atrioventricular block before the procedure (in absence of a functional permanent pacemaker)
- Severe hypotension
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Microvascular function in patients undergoing Transcatheter Aortic Valve Implant (TAVI) for severe symptomatic aortic stenosis: association with myocardial fibrosis
The group in the trial
- Coronary physiology evaluationTreatment being tested
Patient will undergo TAVI and then Myocardial fibrosis will be evaluated on images acquired at the time of the cardiac CT obtained for TAVI planning. Briefly, an extra late post-contrast acquisition image will be acquired. The delayed post-contrast scan will be reconstructed with a soft convolution kernel and will be reformatted in the short- and long-axis planes (slice thickness 8 mm; gap 0 mm) in average mode.
Treatment: coronary physiology
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 30 March 2026